"Recombinant Interferon alfa-2b (Intron A(R)) and Oral Ribavirin (Rebetol): Combination Treatment for Chronic Hepatitis C."

According to an abstract submitted by the author to the 19th US-Japan Hepatitis Joint Panel Meeting, held January 27-29, 1998, at the Asilomar Conference Center in Pacific Grove, California, "Presenting for the International Hepatitis Interventional Therapy Group. Chronic hepatitis C is a common and slowly progressive form of liver disease. Nearly 4 million people are infected with the hepatitis C virus (HCV) in the United States. It is the most common cause of chronic liver disease and is the most common indication for liver transplantation in the U.S. Recombinant interferon alfa-2b (IFN) was approved for treatment of chronic hepatitis C in 1990, but a eradication of HCV was unusual...

Want to see the full article?

• Purchase this article for only $3.00